Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 49893 results
Allergan completes acquisition of Tobira Therapeutics
Allergan (AGN) has completed the acquisition of Tobira Therapeutics (TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases.
News
Portola expands collaboration with Daiichi to develop AndexXa in Germany
Portola Pharmaceuticals (PTLA) has expanded its existing clinical collaboration agreement with Daiichi Sankyo to develop AndexXa (andexanet alfa) as an antidote for the former’s Factor Xa inhibitor named as edoxaban.
Production & Manufacturing > Manufacturing > News
Nimbus secures $200m from Gilead for inhibitor program acquisition
Nimbus Therapeutics secured a $200m from Gilead Sciences in a payment related to the latter’s allosteric Acetyl-CoA Carboxylase (ACC) inhibitor program with NDI-010976 (now GS-0976) which was previously acquired from Nimbus.
Production & Manufacturing > Manufacturing > News
Celgene and IBM Watson to develop new offering for patient safety monitoring
Celgene and IBM Watson Health will co-develop a new offering that aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions.
Production & Manufacturing > Manufacturing > News
Valeant in talks to divest gastroenterology business unit
By PBR Staff Writer
Valeant Pharmaceuticals International is in talks with third parties to divest its various assets, including Salix gastroenterology business unit.
Production & Manufacturing > Manufacturing > News
Aralez acquires US rights to AstraZeneca high blood pressure drug Toprol-XL
By PBR Staff Writer
Aralez Pharmaceuticals Trading DAC (Aralez Ireland) has acquired the US rights to AstraZeneca’s generic high blood pressure drug Toprol-XL.
Contract Research & Services > Contract Services > News
Acadia starts phase II study of pimavanserin in Alzheimer’s disease agitation
Acadia Pharmaceuticals has started SERENE, a Phase II study with pimavanserin for the treatment of agitation in patients with Alzheimer’s disease (AD Agitation).
Contract Research & Services > Clinical Trials > News
Catalyst receives SPA from the FDA for second phase 3 trial assessing firdapse to treat LEMS
Catalyst Pharmaceuticals has reached an agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in its upcoming Phase 3 study assessing Firdapse (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Contract Research & Services > Contract Services > News
Therapix completes formulation development for tablet for sublingual administration of pharmaceutical use
Therapix Biosciences has completed the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use.
Drug Research > Drug Delivery > News
EMA validates avelumab MAA for rare skin cancer
By PBR Staff Writer
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for avelumab for the proposed indication of metastatic Merkel cell carcinoma (MCC).
Production & Manufacturing > Process & Production > News
FDA delays approval of Sanofi and Regeneron's rheumatoid arthritis drug sarilumab
By PBR Staff Writer
The US Food and Drug Administration (FDA) has delayed approval for Sanofi and Regeneron Pharmaceuticals' experimental treatment for rheumatoid arthritis (RA) due to manufacturing deficiencies.
Production & Manufacturing > Manufacturing > News
EC grants orphan drug designation to Philogen's soft tissue sarcoma treatment
Philogen has secured Orphan Drug Designation from the European Commission (EC) to L19TNF - a non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format - for the treatment of soft-tissue sarcoma.
Drug Research > Drug Delivery > News
EMA accepts to evaluate PharmaMar's MAA for Aplidin
The European Medicines Agency (EMA) has accepted to assess PharmaMar's Marketing Authorization Application (MAA) for Aplidin (plitidepsin) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM).
Production & Manufacturing > Process & Production > News
Eisai starts two phase III studies for antiepileptic drug perampanel
Eisai has started two phase III clinical studies for its in-house-discovered antiepileptic drug (AED) perampanel (generic name: perampanel hydrate, product name: Fycompa) as adjunctive therapy in pediatric patients with partial-onset seizures or primary generalized tonic-clonic seizures (Study 311) and in patients with seizures associated with Lennox-Gastaut syndrome (LGS, Study 338).
Contract Research & Services > Clinical Trials > News
Astellas to acquire Ganymed Pharmaceuticals in EUR1.28bn deal
By PBR Staff Writer
Japan’s Astellas Pharma has agreed to acquire Germany-based Ganymed Pharmaceuticals in a deal that could potentially reach €1.28bn.
Drug Research > Drug Discovery & Development > News
136-150 of 49893 results